The Effect of Surveillance on the Outcome of Breast Cancer Patients
K Anvari
1
,
Azar Fanipakdel
1
, *
and
Y Davoudi
2
1 Cancer Research Center, Omid Hospital ,Faculty of Medicine, Mashad University of Medical Sciences, Mashad, Iran
2 Dept. of Radiology, Imam Reza Hospital, Mashad University of Medical Sciences, Mashad, Iran
*
Corresponding author: Azar Fanipakdel, Cancer Research Center, Omid Hospital ,Faculty of Medicine, Mashad University of Medical Sciences, Mashad, Iran, Tel: +98-5118426082, E-mail:
fanipa@mums.ac.ir
International Journal of Cancer Management: March 31, 2013, 6 (1) ; e80379
Published Online :
March 30, 2013
Article Type: Research Article
Received:
April 29, 2012
Accepted:
October 15, 2012
To Cite:
Anvari
K, Fanipakdel
A, Davoudi
Y. The Effect of Surveillance on the Outcome of Breast Cancer Patients,
Int J Cancer Manag.
2013
; 6(1):e80379.
Abstract
Background: The beginning of metastasis poorly affects the prognosis of breast cancer patients. Lung is the most frequent site of visceral metastasis, and the rate of recurrence is 10-30%. We have tried to find out if the routine Chest X Ray (CXR) could play a role for early detection of lung metastasis, during the prognosis of these patients.
Methods: The files of the breast cancer patients between 1996 to 2006 (1739 patients) have reviewed. Clinical characteristics of patients with pulmonary metastasis have recorded. Patients, who lacked imaging files or lacked an appropriate follow-up, have excluded. Data have analyzed by SPSS 11.5. The survival analyses have performed by using the Kaplan-Meier method.
Results: Fifty-six patients, median age 46, have entered into this retrospective study. Median tumor size was 4cm; median number of Lymphadenopathy (LAP) was 4. The intermediate grade has detected in 74% of patients. All patients have received adjuvant treatment. Median time from cancer diagnosis to pulmonary metastasis was 22 months. Pulmonary metastasis has detected by control CXR in 77.4% and patients' symptoms in 22.6%. Forty eight patients have received chemotherapy in metastatic phase. In 28 patients (50%), other sites of metastasis (bone, liver, and brain) have discovered. The most frequent pattern of lung recurrence was pulmonary nodule (44.6%), followed by pleural effusion (28.6%). Median survival was 27.5; median survival from pulmonary metastasis was 8 m.
Conclusion: Early detection of pulmonary metastasis by CXR did not affect patients' endpoints. None of the probable prognostic factors have shown a significant effect on patients' outcome. Despite systemic treatment, survival after metastasis is low.
© 2013, Author(s). This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited.
Except where otherwise noted, this work is licensed under
Creative Commons Attribution Non Commercial 4.0 International License .
Readers' Comments